By Elena Vardon C4X Discovery Holdings on Tuesday said it is selling the proprietary rights to its oral Orexin-1 receptor antagonist for substance use.
By Joe Hoppe Indivior said Thursday that pretax profit and revenue for the second quarter rose on strong sales volume growth, and raised its full-year.